High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers

Paula Vainio; Laura Lehtinen; Mika Hilvo; T. Mirtti; John Mpindi; Pekka Kohonen; Vidal Fey; Kirsi Ketola; K. Alanen; Merja Perälä; Matej Oresic; Olli Kallioniemi; Kristiina Iljin

High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers

Paula Vainio, Laura Lehtinen, Mika Hilvo, T. Mirtti, John Mpindi, Pekka Kohonen, Vidal Fey, Kirsi Ketola, K. Alanen, Merja Perälä, Matej Oresic, Olli Kallioniemi, Kristiina Iljin

Research output: Contribution to conference › Conference article › Scientific

Original language	English
Publication status	Published - 2010
MoE publication type	Not Eligible
Event	Insights in Cancer Progression and Invasion - Helsinki, Finland Duration: 3 Jun 2010 → 4 Jun 2010

Conference

Conference	Insights in Cancer Progression and Invasion
Country	Finland
City	Helsinki
Period	3/06/10 → 4/06/10

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Cite this

Vainio, P., Lehtinen, L., Hilvo, M., Mirtti, T., Mpindi, J., Kohonen, P., Fey, V., Ketola, K., Alanen, K., Perälä, M., Oresic, M., Kallioniemi, O., & Iljin, K. (2010). High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers. Paper presented at Insights in Cancer Progression and Invasion, Helsinki, Finland.

Vainio, Paula ; Lehtinen, Laura ; Hilvo, Mika ; Mirtti, T. ; Mpindi, John ; Kohonen, Pekka ; Fey, Vidal ; Ketola, Kirsi ; Alanen, K. ; Perälä, Merja ; Oresic, Matej ; Kallioniemi, Olli ; Iljin, Kristiina. / High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers. Paper presented at Insights in Cancer Progression and Invasion, Helsinki, Finland.

@conference{f80512850d554fe19a712598d75cf802,

title = "High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers",

author = "Paula Vainio and Laura Lehtinen and Mika Hilvo and T. Mirtti and John Mpindi and Pekka Kohonen and Vidal Fey and Kirsi Ketola and K. Alanen and Merja Per{\"a}l{\"a} and Matej Oresic and Olli Kallioniemi and Kristiina Iljin",

year = "2010",

language = "English",

note = "Insights in Cancer Progression and Invasion ; Conference date: 03-06-2010 Through 04-06-2010",

}

Vainio, P, Lehtinen, L, Hilvo, M, Mirtti, T, Mpindi, J, Kohonen, P, Fey, V, Ketola, K, Alanen, K, Perälä, M, Oresic, M, Kallioniemi, O & Iljin, K 2010, 'High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers', Paper presented at Insights in Cancer Progression and Invasion, Helsinki, Finland, 3/06/10 - 4/06/10.

High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers. / Vainio, Paula; Lehtinen, Laura; Hilvo, Mika; Mirtti, T.; Mpindi, John; Kohonen, Pekka; Fey, Vidal; Ketola, Kirsi; Alanen, K.; Perälä, Merja; Oresic, Matej; Kallioniemi, Olli; Iljin, Kristiina.

2010. Paper presented at Insights in Cancer Progression and Invasion, Helsinki, Finland.

Research output: Contribution to conference › Conference article › Scientific

TY - CONF

T1 - High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers

AU - Vainio, Paula

AU - Lehtinen, Laura

AU - Hilvo, Mika

AU - Mirtti, T.

AU - Mpindi, John

AU - Kohonen, Pekka

AU - Fey, Vidal

AU - Ketola, Kirsi

AU - Alanen, K.

AU - Perälä, Merja

AU - Oresic, Matej

AU - Kallioniemi, Olli

AU - Iljin, Kristiina

PY - 2010

Y1 - 2010

M3 - Conference article

T2 - Insights in Cancer Progression and Invasion

Y2 - 3 June 2010 through 4 June 2010

ER -